Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537787 | 0.84 | CYP4F2 (0.43) | CYP4F2CYP4A11PTGER4ALDH1A1KDM4E | |
| SCHEMBL3532318 | 0.79 | PTGER4 (0.41) | CYP4F2CYP4A11PTGER4ALDH1A1KDM4E | |
| SCHEMBL17537839 | 0.75 | CYP4F2 (0.56) | CYP4F2CYP4A11ALDH1A1KDM4EHPGD | |
| SCHEMBL17895868 | 0.73 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL8824436 | 0.71 | ALDH1A1 (0.57) | CYP4F2CYP4A11ALDH1A1KDM4EHPGD | |
| SCHEMBL22098182 | 0.71 | CYP4F2 (1.00) | CYP4F2CYP4A11ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL20289308 | 0.71 | CYP4F2 (0.64) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7522054 | 0.71 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7030964 | 0.71 | MAOB (0.50) | CYP4F2CYP4A11ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14200101 | 0.70 | PTGER4 (0.54) | PTGER4ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | CYP4F2 439/4885CYP4A11 216/4885PTGER4 1/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | CYP4F2 439/4885CYP4A11 195/4885PTGER4 1/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | CYP4F2 462/4885CYP4A11 224/4885PTGER4 1/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | CYP4F2 437/4885CYP4A11 233/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.